HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real time*
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX iQ™ with HFX AdaptivAI™ – a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.
Building on a foundation of landmark evidence2, clinical research and big data, HFX AdaptivAI is the only technology with artificial intelligence (AI) to provide patients suffering from chronic pain with an unprecedented level of personalized, responsive pain relief.
“Nevro is further establishing its position as the leading developer of data-driven solutions for pain management through the launch of HFX iQ with HFX AdaptivAI,” said Kevin Thornal, Nevro’s CEO and president. “HFX AdaptivAI delivers personalized pain relief, utilizing AI and leveraging millions of data points and ten years of innovation and patient care. We believe this new solution is a major milestone, and it demonstrates our dedication to freeing patients from the burden of chronic pain through evidence-based therapies that transform patients’ lives. Importantly, HFX AdaptivAI puts patients in control of their pain relief while, at the same time, providing physicians the ability to monitor their patient’s pain journey – closing the loop that matters.”
“HFX AdaptivAI is a significant leap forward in pain management,” said Dr. Usman Latif, MD, MBA, a Harvard-trained interventional pain specialist at The University of Kansas Health System. “Drawing from landmark evidence and big data, this technology has the potential to offer patients a faster and more sustainable approach to pain relief. HFX AdaptivAI is on the right path to make a lasting impact on how we manage chronic pain and improve patient outcomes.”
HFX AdaptivAI Offers:
- Relief and Beyond: HFX AdaptivAI is engineered to maximize pain relief over time by continuing to optimize therapy even when pain relief over 50% has been achieved1.
- Bipole Interlacing™: Proprietary technology creates customized therapy programs in real-time using direct patient input1**.
- Smart Power: Through therapy optimization, advanced Smart Power technology allows patients to charge their device as little as six times per year3.
- Enhanced Real-Time Insights: HFX AdaptivAI technology gathers real-time quality of life (QoL) metrics and device data, enabling more impactful patient-clinician interactions. This real-time information helps patients report pain relief in significantly less time than with traditional programming¹.
- Advanced Proactive Remote Monitoring: With the launch of HFX AdaptivAI, physicians will have the ability to remotely monitor each of their patient’s pain journey in real time through Nevro’s healthcare provider portal.
“Chronic pain is a dynamic, biopsychosocial human condition unique to each individual4,” said Dr. David Caraway, MD, PhD, Nevro’s chief medical officer. “To effectively treat suffering – as perceived by each patient – therapies must be personalized based on the changing experience of pain. Only HFX AdaptivAI seeks to engage with the patient and personalize the SCS therapy in real time using evidence based on algorithms and multi-dimensional metrics of pain relief, function and satisfaction.”
Nevro noted that it expects to launch its full market release of HFX iQ with HFX AdaptivAI in the U.S. in the fourth quarter of 2024.
For more information on HFX AdaptivAI, please visit https://nevro.com/English/us/providers/Product-HFX-AdaptivAI.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!
